Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005993 | 1.00 | AAK1 (0.31) | AAK1FPR3FPR2FAAHBACE1 | |
| SCHEMBL23005999 | 1.00 | AAK1 (0.31) | AAK1FPR3FPR2FAAHBACE1 | |
| SCHEMBL23006160 | 0.90 | TP53 (0.34) | FAAH | |
| SCHEMBL29862346 | 0.90 | TP53 (0.34) | FAAH | |
| SCHEMBL23005914 | 0.90 | USP30 (0.31) | FAAH | |
| SCHEMBL22983887 | 0.90 | — | — | |
| SCHEMBL23006415 | 0.88 | DGAT1 (0.35) | FPR3FPR2IDO1TDO2 | |
| SCHEMBL29862136 | 0.88 | DGAT1 (0.35) | FPR3FPR2IDO1TDO2 | |
| SCHEMBL23006414 | 0.88 | DGAT1 (0.35) | FPR3FPR2IDO1TDO2 | |
| SCHEMBL29862207 | 0.88 | ADORA2B (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-06 | — | — | US | disclosed |
| EP-4013759-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | AAK1 3729/4885FPR3 1648/4885FPR2 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.